GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR

gurujx

gurujx

1 followers
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Core Laboratories N.V, CEPHEID, Alexion Pharmaceuticals Inc, Ardea Biosciences, and C.R. Bard Inc.

Core Laboratories N.V. (CLB): EVP, CFO & Treasurer Richard L Bergmark Sold 50,000 Shares

EVP, CFO & Treasurer of Core Laboratories N.V. (CLB) Richard L Bergmark sold 50,000 shares on 07/25/2011 at an average price of $111.76. Based in the Netherlands, Core Laboratories provides geological andenvironmental analysis services and manufactures precise measurementequipment. Core Laboratories N.v. has a market cap of $4.95 billion; its shares were traded at around $108.68 with a P/E ratio of 32.8 and P/S ratio of 6.3. The dividend yield of Core Laboratories N.v. stocks is 0.9%. Core Laboratories N.v. had an annual average earnings growth of 28.7% over the past 10 years. GuruFocus rated Core Laboratories N.v. the business predictability rank of 4.5-star.

Core Laboratories N.V. recently reported its second quarter 2011 results. For this quarter, the company posted total revenues of $225.8 million – up 13.5% from the $198.9 million prior year quarter. EPS was 90 cents compared to 71 cents prior year quarter, with a total net income of $40.45 million compared to $34.22 million last year.

CEO David M Demshur sold 200,000 shares of CLB stock on 07/27/2011 at the average price of 109.26. EVP, CFO & Treasurer Richard L Bergmark sold 50,000 shares of CLB stock on 07/25/2011 at the average price of 111.76. Richard L Bergmark owns at least 121,054 shares after this. The price of the stock has decreased by 2.76% since. Other insiders sold shares of CLB stock during the past week as well.

CEPHEID (CPHD): CFO Andrew Miller Sold 50,000 Shares

CFO of CEPHEID (CPHD) Andrew Miller sold 50,000 shares on 07/26/2011 at an average price of $39.67. Cepheid, Inc. develops, manufactures and markets microfluidic systems that integrate, automate and accelerate biological testing. Cepheid has a market cap of $2.33 billion; its shares were traded at around $37.76 with a P/E ratio of 755.2 and P/S ratio of 11.1.

For its second quarter 2011, CEPHEID reported total revenues of $67 million compared to $49.6 million prior year quarter. GAAP Net income for the company was $1.8 million compared to a net loss of $1.8 million last year. Non-GAAP Net income was $7.2 million compared to $2.9 million prior year quarter. Total product sales were $63.6 million compared to $48.6 million last year.

CFO Andrew Miller sold 50,000 shares of CPHD stock on 07/26/2011 at the average price of 39.67. Andrew Miller owns at least 2,500 shares after this. The price of the stock has decreased by 4.81% since. Executive VP, COO Humberto Reyes sold 325,000 shares of CPHD stock on 07/25/2011 at the average price of 39.65. Sr. VP, Regulatory Russell Enns sold 30,000 shares of CPHD stock on 07/22/2011 at the average price of 39.85.

Alexion Pharmaceuticals Inc. (ALXN): SVP & CFO Vikas Sinha Sold 26,305 Shares

SVP & CFO of Alexion Pharmaceuticals Inc. (ALXN) Vikas Sinha sold 26,305 shares on 07/27/2011 at an average price of $58.33. Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. Alexion Pharmaceuticals Inc. has a market cap of $10.44 billion; its shares were traded at around $56.8 with a P/E ratio of 68.1 and P/S ratio of 19.3.

For its second quarter 2011, Alexion Pharmaceuticals Inc. reported revenues of $185.7 million compared to $125.8 million priory year quarter. Total net income was $34.7 million – a 60% increase from $21.8 million last year. Sales of the company’s Solaris increased 48% to $185.7 million from last year.

CEO Leonard Bell sold 2,285 shares of ALXN stock on 07/27/2011 at the average price of 57.27. SVP & CFO Vikas Sinha sold 26,305 shares of ALXN stock on 07/27/2011 at the average price of 58.33. Vikas Sinha owns at least 352,103 shares after this. The price of the stock has decreased by 2.62% since. SVP. Global Commercial Ops David Hallal sold 37,427 shares of ALXN stock on 07/28/2011 at the average price of 57.33. Director Joseph A Madri sold 30,000 shares of ALXN stock on 07/27/2011 at the average price of 56.53. Other insiders sold shares of ALXN stock during the past week as well.

Ardea Biosciences Inc. (RDEA): SVP, Finance & Operations, CFO John W Beck Sold 16,000 Shares

SVP, Finance & Operations, CFO of Ardea Biosciences Inc. (RDEA) John W Beck sold 16,000 shares on 07/25/2011 at an average price of $24.46. IntraBiotics Pharmaceuticals, Inc. develops and intends to commercialize new antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. Ardea Biosciences Inc. has a market cap of $624.1 million; its shares were traded at around $23.4 with and P/S ratio of 22.8.

Ardea Biosciences Inc. has released its first quarter 2011 results. The company reported revenues of $1.8 million compared to $3.3 million prior year quarter. Net loss during the quarter was $15.2 million compared with a net loss of $10.1 million last year.

SVP, Finance & Operations, CFO John W Beck sold 16,000 shares of RDEA stock on 07/25/2011 at the average price of 24.46. John W Beck owns at least 4,409 shares after this. The price of the stock has decreased by 4.33% since. SVP, Regulatory & Dev Ops Kimberly Manhard sold 5,000 shares of RDEA stock on 07/28/2011 at the average price of 23.56.

C.R. Bard Inc. (BCR): Senior Vice President and CFO Todd C Schermerhorn Sold 33,400 Shares

Senior Vice President and CFO of C.R. Bard Inc. (BCR) Todd C Schermerhorn sold 33,400 shares on 07/22/2011 at an average price of $100.5. C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. C.r. Bard Inc. has a market cap of $8.45 billion; its shares were traded at around $98.68 with a P/E ratio of 16.3 and P/S ratio of 3.2. The dividend yield of C.r. Bard Inc. stocks is 0.8%. C.r. Bard Inc. had an annual average earnings growth of 15.6% over the past 10 years. GuruFocus rated C.r. Bard Inc. the business predictability rank of 5-star.

During its second quarter 2011, C.R.Bard Inc. reported net loss of $47.8 million compared to a net income of $124.6 million last year. Revenues increased 7.6% to $725 million from last year.

Senior Vice President and CFO Todd C Schermerhorn sold 33,400 shares of BCR stock on 07/22/2011 at the average price of 100.5. Todd C Schermerhorn owns at least 119,481 shares after this. The price of the stock has decreased by 1.81% since.

For the complete list of stocks that Sold by their CFOs, go to: Insider Buys.

  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership


Rating: 2.3/5 (11 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide